Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
about
Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewHepatic methotrexate content and progression of hepatic fibrosis: preliminary findingsMethotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough?Intestinal and liver toxicity of antineoplastic drugs.Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymesThe pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.Liver disease after bone marrow transplantation.Hepatotoxicity of methotrexate in rheumatic diseases.Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax.Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?Long-term effects on the liver.Central role of mitochondria in drug-induced liver injury.A review of methotrexate-associated hepatotoxicity.Methotrexate in rheumatoid arthritis: an update.Psoriasis and its treatment.The Potential Use of Methotrexate in the Treatment of Cutaneous Leishmaniasis: In Vitro Assays against Sensitive and Meglumine Antimoniate-resistant Strains of Leishmania tropicaHistopathological effects of methotrexate on mouse liverHepatotoxicity associated with low-dose, long-term methotrexate treatment of rheumatoid arthritis.Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy.Evidence against the role of hepatitis C virus in severe liver damage occurring early in the course of acute leukemia in children.Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients.Liver histology after current intensified therapy for childhood acute lymphoblastic leukemia: microvesicular fatty change and siderosis are the main findings.Points: Hypoglycaemia and acute myelomonocytic leukaemia.Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study.
P2860
Q26995202-85946B65-1789-409C-950B-FE01D783319BQ33563722-B16CC3B2-7330-42B9-8AA2-F4E98D307B64Q33565153-AD6475DD-59B7-415F-BD04-83F4A1E093CFQ33605823-C64EEBD5-53ED-4957-8535-E9FF9B396DA3Q34153004-BCC60C6E-7724-4321-9CCD-A22BCFC357CBQ34403636-4D373516-0A75-46D5-B538-DD9202548172Q34495051-FA7B2FAB-3838-450F-B1E6-57B284D4D378Q34684662-F87E938A-7C1D-4919-BDDF-B7FC2265168EQ34763470-3A3E8DB0-5B37-4FC7-8A80-F24A67FFE707Q36683921-1C98B5DA-4E82-49AA-965B-679A0718FC91Q37084032-EFB7BBAE-D4CE-41BC-B6E4-748F73B05E3FQ37926590-6B3B53EA-077D-4F65-9C93-A02FBE67FE0CQ38241492-ABCB93DA-3B58-4B6E-AD9B-C3FC7C198F74Q39746666-65CACF2A-41D2-4694-94E7-11FCCDFD3094Q40259463-50DE87EC-302A-49B2-BE0B-3C4CC9495C16Q41872288-7B0E0518-AFB8-45B9-B329-9D4E9852BA4DQ42115156-88C6192B-DC44-4433-8149-4DF014E9F947Q42219349-C6A63644-A0B0-4EEC-B2F5-66FB28737329Q42555875-143545A8-9A83-44F6-9B43-569FEA9BE57CQ43035904-B1004FBA-9474-4D7B-9DE5-E37AE658D1E1Q43859680-4F27A661-9E4D-4AB2-9DCE-4750797EEA92Q44272409-D7F462A8-67C9-436D-98BC-532A4B1AA903Q46251654-22267E55-87C6-489E-8462-B3578B5AED64Q54531001-19FC8233-E255-405B-87EA-7C52CC5873D5
P2860
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
description
1972 nî lūn-bûn
@nan
1972 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի մարտին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@ast
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@en
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@nl
type
label
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@ast
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@en
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@nl
prefLabel
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@ast
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@en
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@nl
P2093
P2860
P356
P1433
P1476
Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens
@en
P2093
M M Gregory
P J Scheuer
P2860
P356
10.1136/BMJ.1.5801.654
P407
P577
1972-03-11T00:00:00Z